A platform for research: civil engineering, architecture and urbanism
A platform for research: civil engineering, architecture and urbanism
Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer
Acquired resistance to hormonal therapy, particularly enzalutamide (ENZ), remains a significant obstacle in the treatment of advanced bone metastatic prostate cancer. Here, it is demonstrated that under ENZ treatment, osteoblasts in the bone microenvironment secrete increased levels of extracellular matrix protein 1 (ECM1), which affects surrounding prostate cancer cells, promoting tumor cell proliferation and anti‐androgen resistance. Mechanistically, ECM1 interacts with the enolase 1 (ENO1) receptor on the prostate cancer cell membrane, leading to its phosphorylation at the Y189 site. This event further recruits adapter proteins including growth factor receptor‐bound protein 2 (GRB2) and son of sevenless homolog 1 (SOS1), which activates the downstream mitogen‐activated protein kinase (MAPK) signaling pathway to induce anti‐androgen resistance. Furthermore, inhibiting ECM1 or utilizing the ENO1‐targeting inhibitor phosphonoacetohydroxamate (PhAH) significantly restores tumor cell sensitivity to ENZ. Taken together, a potential mechanism is identified through which osteoblast‐derived ECM1 drives resistance in bone metastatic prostate cancer under ENZ treatment. Additionally, the findings indicate that ECM1 and ENO1 may serve as potential targets for developing therapies for bone metastatic castration‐resistant prostate cancer.
Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer
Acquired resistance to hormonal therapy, particularly enzalutamide (ENZ), remains a significant obstacle in the treatment of advanced bone metastatic prostate cancer. Here, it is demonstrated that under ENZ treatment, osteoblasts in the bone microenvironment secrete increased levels of extracellular matrix protein 1 (ECM1), which affects surrounding prostate cancer cells, promoting tumor cell proliferation and anti‐androgen resistance. Mechanistically, ECM1 interacts with the enolase 1 (ENO1) receptor on the prostate cancer cell membrane, leading to its phosphorylation at the Y189 site. This event further recruits adapter proteins including growth factor receptor‐bound protein 2 (GRB2) and son of sevenless homolog 1 (SOS1), which activates the downstream mitogen‐activated protein kinase (MAPK) signaling pathway to induce anti‐androgen resistance. Furthermore, inhibiting ECM1 or utilizing the ENO1‐targeting inhibitor phosphonoacetohydroxamate (PhAH) significantly restores tumor cell sensitivity to ENZ. Taken together, a potential mechanism is identified through which osteoblast‐derived ECM1 drives resistance in bone metastatic prostate cancer under ENZ treatment. Additionally, the findings indicate that ECM1 and ENO1 may serve as potential targets for developing therapies for bone metastatic castration‐resistant prostate cancer.
Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer
Wang, Xinwen (author) / Wang, Min (author) / Lin, Qijun (author) / He, Lixin (author) / Zhang, Baolin (author) / Chen, Xin (author) / Chen, Guanhong (author) / Du, Hong (author) / Lang, Chuandong (author) / Peng, Xinsheng (author)
Advanced Science ; 12
2025-01-01
22 pages
Article (Journal)
Electronic Resource
English
Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer
| Wiley | 2025
Paired box2 upregulates androgen receptor gene expression in androgen-independent prostate cancer
| British Library Online Contents | 2014
Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
| Springer Verlag | 2024
Biomimetic nanocoating promotes osteoblast cell adhesion on biomedical implants
| British Library Online Contents | 2008
UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer
| Wiley | 2024